- Home
- ARGX vs MRVL Comparison
ARGX vs MRVL Comparison
Compare ARGX & MRVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- MRVL
- Stock Information
- Founded
- ARGX 2008
- MRVL 1995
- Country
- ARGX Netherlands
- MRVL United States
- Employees
- ARGX N/A
- MRVL N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- MRVL Semiconductors
- Sector
- ARGX Health Care
- MRVL Technology
- Exchange
- ARGX Nasdaq
- MRVL Nasdaq
- Market Cap
- ARGX 48.2B
- MRVL 54.6B
- IPO Year
- ARGX 2017
- MRVL 2000
- Fundamental
- Price
- ARGX $830.94
- MRVL $88.27
- Analyst Decision
- ARGX Strong Buy
- MRVL Buy
- Analyst Count
- ARGX 18
- MRVL 31
- Target Price
- ARGX $813.82
- MRVL $94.68
- AVG Volume (30 Days)
- ARGX 335.2K
- MRVL 22.9M
- Earning Date
- ARGX 10-30-2025
- MRVL 12-02-2025
- Dividend Yield
- ARGX N/A
- MRVL 0.27%
- EPS Growth
- ARGX N/A
- MRVL N/A
- EPS
- ARGX 18.75
- MRVL N/A
- Revenue
- ARGX $3,120,821,000.00
- MRVL $7,234,900,000.00
- Revenue This Year
- ARGX $81.74
- MRVL $43.81
- Revenue Next Year
- ARGX $31.91
- MRVL $15.87
- P/E Ratio
- ARGX $39.68
- MRVL N/A
- Revenue Growth
- ARGX 88.04
- MRVL 37.05
- 52 Week Low
- ARGX $510.06
- MRVL $47.09
- 52 Week High
- ARGX $838.07
- MRVL $127.48
- Technical
- Relative Strength Index (RSI)
- ARGX 75.79
- MRVL 59.49
- Support Level
- ARGX $793.60
- MRVL $85.33
- Resistance Level
- ARGX $808.43
- MRVL $94.65
- Average True Range (ATR)
- ARGX 15.74
- MRVL 3.54
- MACD
- ARGX 3.08
- MRVL -0.04
- Stochastic Oscillator
- ARGX 95.87
- MRVL 52.03
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About MRVL Marvell Technology Inc.
Marvell Technology is a fabless chip designer focused on wired networking, where it has the second-highest market share. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical and copper transceivers, switches, and storage controllers.